ClinicalTrials.gg
CompletedNCT00430352Updated Aug 14, 2017Results posted

MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

A Phase 4 interventional study of rituximab [MabThera/Rituxan] in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 178 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-14.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2006, registered Jan 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
545
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
9th of 171
545 · median 38
Started
2006
with 16 others
Phase 4
5 of 178
none open now
Registered
74th of 178
by date
Lead sponsor
13 of 178
Hoffmann-La Roche

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 9th largest by enrollment of the 171 interventional ones that give a count, is one of 17 that started in 2006, is one of 5 in phase 4, and was the 74th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma. All patients will receive MabThera 375mg/m2 body surface area, as an intravenous infusion, every 8 weeks. The anticipated time on study treatment is 1-2 years, and the target sample size is 500+ individuals.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • confirmed grade 1, 2 or 3a follicular non-Hodgkin's lymphoma;
  • patients who have received adequate (>=8 cycles) induction therapy with MabThera as treatment, or treatment for disease;
  • demonstrated partial or complete response to induction therapy.

Exclusion criteria

Exclusion Criteria:

  • stable or progressive disease after most recent induction therapy;
  • transformation to high grade lymphoma;
  • patients with prior or concomitant , except non-melanoma skin cancer or adequately treated in situ cancer of the cervix.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
545 participants (actual)

Study arms

  • Experimental
    1

    Drug: rituximab [MabThera/Rituxan]

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    375mg/m2 iv every 8 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Adverse Event (AE) - Overall Summary

    Data presented include percentage of participants with any AE, any infusion-related AE, any serious adverse event (SAE), any infusion-related SAE (counted separately from SAEs), death, and participants with toxicity as the primary cause for treatment discontinuation.

    Time frame: 24 months

Secondary outcomes

  1. Progression-Free Survival - Percentage of Participants With an Event

    PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.

    Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose

  2. Progression-Free Survival - Time to Event

    PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.

    Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose

  3. Event-Free Survival (EFS) - Percentage of Participants With an Event

    The percentage of participants who experienced PD or death or required a next or new lymphoma treatment over a study period of 2 years with 1 year of follow-up. EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.

    Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose

  4. Event-Free Survival (EFS) - Time to Event

    EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.

    Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose

  5. Overall Survival (OS) - Percentage of Participants With an Event

    As a measure of overall survival (OS), the percentage of participants who died over the study period of 2 years with 1 year of follow-up. OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.

    Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose

  6. Overall Survival (OS) - Time to Event

    OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.

    Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose

  7. Time to Next Lymphoma Treatment (NLT) - Percentage of Participants With an Event

    As a measure of time to NLT (TNLT), the percentage of participants with new lymphoma treatment over a study period of 2 years with 1 year of follow-up. TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.

    Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose

  8. Time to NLT - Time to Event

    TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.

    Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose

  9. Percentage of Participants With Response by Best Response to Study Treatment

    Percentage of participants with complete response (CR), unconfirmed CR (CRu), no change, or progressive disease (PD). For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Where possible, assessment of response was based on the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma (NHL).

    Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose

  10. Percentage of Participants With PR Who Converted to CRu

    Percentage of participants with PR or CR(u) conversion while on rituximab maintenance therapy over a study period of 2 years with 1 year of follow-up. For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Assessment and definition of response was based on the International Workshop to Standardize Response Criteria for NHL.

    Time frame: Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose

07

Results

Posted Jun 8, 2015

Participant flow

Participant flow — Overall Study
MilestoneRituximab 375 Milligrams Per Square Meter (mg/m^2)
Started545
Completed407
Not completed138
Withdrew: Disease progression58
Withdrew: Withdrawal by subject11
Withdrew: Adverse event16
Withdrew: Death5
Withdrew: Other48

Outcome measures

PrimaryPercentage of Participants With an Adverse Event (AE) - Overall Summary

Data presented include percentage of participants with any AE, any infusion-related AE, any serious adverse event (SAE), any infusion-related SAE (counted separately from SAEs), death, and participants with toxicity as the primary cause for treatment discontinuation.

Time frame:
24 months
Reported as:
Number · percentage of participants
Percentage of Participants With an Adverse Event (AE) - Overall Summary
percentage of participantsRituximab 375 mg/m^2
Any AE67.4
Any infusion-related AE5.8
Any non-infusion related SAE20.2
Any infusion-related SAE0.2
Deaths7.5
Toxicity as primary cause for discontinuation3.0
SecondaryProgression-Free Survival - Percentage of Participants With an Event

PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.

Time frame:
Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Reported as:
Number · percentage of participants
Progression-Free Survival - Percentage of Participants With an Event
percentage of participantsRituximab 375 mg/m^2
Progression-Free Survival - Percentage of Participants With an Event24.0
SecondaryProgression-Free Survival - Time to Event

PFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression or death by any cause. Participants who experienced none of these events at the time of analysis (clinical cutoff) and participants who were lost to follow-up were censored at their last clinical assessment date.

Time frame:
Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Reported as:
Median · months
Progression-Free Survival - Time to Event
monthsRituximab 375 mg/m^2
Progression-Free Survival - Time to EventNA (NA to NA)
SecondaryEvent-Free Survival (EFS) - Percentage of Participants With an Event

The percentage of participants who experienced PD or death or required a next or new lymphoma treatment over a study period of 2 years with 1 year of follow-up. EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.

Time frame:
Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Reported as:
Number · percentage of participants
Event-Free Survival (EFS) - Percentage of Participants With an Event
percentage of participantsRituximab 375 mg/m^2
Event-Free Survival (EFS) - Percentage of Participants With an Event24.4
SecondaryEvent-Free Survival (EFS) - Time to Event

EFS was measured from the day of first rituximab maintenance infusion until the date of first documented disease progression, death by any cause, or the institution of new anti-lymphoma treatment. Participants who experienced none of these events at the end of the study and participants who were lost to follow-up were censored at their last clinical assessment date.

Time frame:
Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Reported as:
Median · months
Event-Free Survival (EFS) - Time to Event
monthsRituximab 375 mg/m^2
Event-Free Survival (EFS) - Time to EventNA (NA to NA)
SecondaryOverall Survival (OS) - Percentage of Participants With an Event

As a measure of overall survival (OS), the percentage of participants who died over the study period of 2 years with 1 year of follow-up. OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.

Time frame:
Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Reported as:
Number · percentage of participants
Overall Survival (OS) - Percentage of Participants With an Event
percentage of participantsRituximab 375 mg/m^2
Overall Survival (OS) - Percentage of Participants With an Event7.3
SecondaryOverall Survival (OS) - Time to Event

OS was determined from the day of first rituximab maintenance infusion until the date of death irrespective of cause. Participants who had not died at the time of end of the whole study and participants who were lost to follow up were censored at the date of the last contact.

Time frame:
Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Reported as:
Median · percentage of participants
Overall Survival (OS) - Time to Event
percentage of participantsRituximab 375 mg/m^2
Overall Survival (OS) - Time to EventNA (NA to NA)
SecondaryTime to Next Lymphoma Treatment (NLT) - Percentage of Participants With an Event

As a measure of time to NLT (TNLT), the percentage of participants with new lymphoma treatment over a study period of 2 years with 1 year of follow-up. TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.

Time frame:
Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Reported as:
Number · percentage of participants
Time to Next Lymphoma Treatment (NLT) - Percentage of Participants With an Event
percentage of participantsRituximab 375 mg/m^2
Time to Next Lymphoma Treatment (NLT) - Percentage of Participants With an Event17.4
SecondaryTime to NLT - Time to Event

TNLT was measured from the date of first rituximab maintenance infusion to the date of first documented intake of any new anti-lymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc). Participants who did not have documentation that an NLT had started and participants who were lost to follow up were censored at their last visit where the assessment for start of any new lymphoma medication was actually made.

Time frame:
Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Reported as:
Median · months
Time to NLT - Time to Event
monthsRituximab 375 mg/m^2
Time to NLT - Time to EventNA (NA to NA)
SecondaryPercentage of Participants With Response by Best Response to Study Treatment

Percentage of participants with complete response (CR), unconfirmed CR (CRu), no change, or progressive disease (PD). For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Where possible, assessment of response was based on the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma (NHL).

Time frame:
Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Reported as:
Number · percentage of participants
Percentage of Participants With Response by Best Response to Study Treatment
percentage of participantsRituximab 375 mg/m^2
CR/CRu2.1
No change87.5
PD10.5
SecondaryPercentage of Participants With PR Who Converted to CRu

Percentage of participants with PR or CR(u) conversion while on rituximab maintenance therapy over a study period of 2 years with 1 year of follow-up. For each participant, the last response to induction therapy immediately prior to study entry was compared to the best response observed during rituximab maintenance therapy. Assessment and definition of response was based on the International Workshop to Standardize Response Criteria for NHL.

Time frame:
Baseline, every 8 weeks during treatment, and 3, 6, 9 and 12 months after last dose
Reported as:
Number · percentage of participants
Percentage of Participants With PR Who Converted to CRu
percentage of participantsRituximab 375 mg/m^2
Percentage of Participants With PR Who Converted to CRu6.2 (3.0 to 11.1)

Adverse events

Collected over AEs were collected at up through 12 months after last dose (1 year follow-up).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab 375 mg/m^2—109/534 (20.4%)207/534 (38.8%)
Most frequent serious events
Showing 10 of 116
Most frequent serious events
EventRituximab 375 mg/m^2
PneumoniaInfections and infestations7/534
PyrexiaGeneral disorders4/534
NeutropeniaBlood and lymphatic system disorders4/534
AppendicitisInfections and infestations3/534
DiarrhoeaGastrointestinal disorders3/534
Cerebral haemorrhageNervous system disorders3/534
DyspnoeaRespiratory, thoracic and mediastinal disorders3/534
Febrile neutropeniaBlood and lymphatic system disorders3/534
SinusitisInfections and infestations2/534
Coronary artery diseaseCardiac disorders2/534
Most frequent other events
Showing 10 of 11
Most frequent other events
EventRituximab 375 mg/m^2
CoughRespiratory, thoracic and mediastinal disorders50/534
FatigueGeneral disorders40/534
NasopharyngitisInfections and infestations38/534
Blood lactate dehydrogenase increasedInvestigations37/534
Back painMusculoskeletal and connective tissue disorders35/534
ArthralgiaMusculoskeletal and connective tissue disorders34/534
HypertensionVascular disorders32/534
DiarrhoeaGastrointestinal disorders31/534
HeadacheNervous system disorders31/534
Neutrophil count decreasedInvestigations29/534

Baseline characteristics

Intent-to-treat (ITT) population: all participants who completed a baseline visit and at least 1 further assessment.

Age, Continuous
Age, Continuous(years)Rituximab 375 mg/m^2
Mean56.3 ± 11.47
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab 375 mg/m^2
Female313
Male232
08

Study locations

178 sites
  • University "Mother Theresa" Hospital Center; Oncology Department
    Tirana, 1000, Albania
  • Instituo Lavalle de Oncologia; Hematology
    Bahia Blanca, 8001, Argentina
  • Academia Nacional de Medicina; Inst. de Cardiologia
    Buenos Aires, 1425, Argentina
  • Fundaleu; Haematology
    Buenos Aires, C1114AAN, Argentina
  • Hospital Churruca Visca; Haematology
    Buenos Aires, C1437JCP, Argentina
  • Hospital Jr Vidal; Jefe de Servicio de Clinica Medica/Hematologia
    Corrientes, 3400, Argentina
  • Sanatorio Allende; Haematology
    Córdoba, 5000, Argentina
  • HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto Oncología
    Córdoba, 5016, Argentina
  • Hospital General San Martin; Haematology
    La Plata, B1904CFS, Argentina
  • Liverpool Hospital; Haematology
    Liverpool, New South Wales 2170, Australia
  • Wollongong Hospital; Cancer Services
    Wollongong, New South Wales 2500, Australia
  • Royal Brisbane Hospital; Oncology Department
    Brisbane, Queensland 4006, Australia
  • Haematology & Oncology Clinics of Australia, Mater Medical Centre
    South Brisbane, Queensland 4101, Australia
  • Mount Medical Center
    Perth, Western Australia 6000, Australia
  • University Clinical Center of the Republic of Srpska, Clinic for Internal Disease, Hematology Dept
    Banja Luka, 88000, Bosnia and Herzegovina
  • Inst. of Hematology
    Kasindo, 71123, Bosnia and Herzegovina
  • Uni Hospital Mostar
    Mostar, 88000, Bosnia and Herzegovina
  • Clinic of Oncology, University Clinical Center Sarajevo
    Sarajevo, 71000, Bosnia and Herzegovina
  • Nucleo de Oncologia da Bahia - NOB
    Salvador, Bahia, BA 40170-380, Brazil
  • CEHON
    Salvador, BA 40110-150, Brazil
  • ONCOMED
    Belo Horizonte, MG 30140-083, Brazil
  • Centro de Tratamento Oncologico - Oncoclinica
    Rio de Janeiro, RJ 22640-000, Brazil
  • Hospital das Clinicas - UFRGS; Medicina Interna
    Porto Alegre, RS 90035-903, Brazil
  • Hospital Mae de Deus
    Porto Alegre, RS 90470-340, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Centro de Pesquisas Oncologicas - CEPON
    Florianopolis, SC 88034-000, Brazil
  • Hospital das Clinicas - UNICAMP; Hemoterapia
    Campinas, SP 13083-878, Brazil
  • Clinica Oncologica De Piracicaba Sc
    Piracicaba, SP 13419-155, Brazil
  • Hospital Alemao Oswaldo Cruz; Oncologia
    Sao Paulo, SP 01323-020, Brazil
  • Hospital Estadual do Servidor Publico; Hematologia
    Sao Paulo, SP 04029-000, Brazil
  • Hospital das Clinicas - FMUSP, Oncologia
    Sao Paulo, SP 05403-000, Brazil
  • UMHAT Dr Georgi Stranski; Hematology
    Pleven, 5800, Bulgaria
  • Umhat S. George; Hematology
    Plovdiv, 4002, Bulgaria
  • UMHAT Alexandrovska EAD; Hematology
    Sofia, 1431, Bulgaria
  • National Center of Hematology & Transfusiology; Clinical Unit, Clinic of Hematology
    Sofia, 1757, Bulgaria
  • Mhat Sveta Marina; Dept. of Haematology
    Varna, 9010, Bulgaria
  • Centro Médico Carlos Ardila Lule
    Bucaramanga, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin-Antioquia, Colombia
  • Clinical Hospital Centre Split; Dept Of Hematology
    Split, 21000, Croatia
  • Clinical Hospital Centre Dubrava; Hematology Department
    Zagreb, 10000, Croatia
  • University Hospital Center Zagreb; Haematology Department
    Zagreb, 10000, Croatia
  • Hospital José Carrasco; Oncology Service
    Cuenca, Ecuador
  • Hospital Carlos Andrade Marin; Servicio de Oncología
    Quito, 2569, Ecuador
  • Oncology & Radiotherapy Centre; Oncology
    Cairo, 11737, Egypt
  • Kanta-Hämeen Keskussairaala; Dept of Internal Medicine, Hematology
    Haemeenlinna, 13530, Finland
  • Kymenlaakson keskussairaala
    Kotka, 48210, Finland
  • Päijät-Hämeen Keskussairaala; Dept of Internal Medicine, Hematology
    Lahti, 15850, Finland
  • Satakunnan Keskussairaala; Sisaetauti Osasto
    Pori, 28500, Finland
  • Internist; Praxis Für Haemotologie & Onkologie
    Bad Soden, 65812, Germany
  • Dres.Christian Sperling und Claudia Schelenz
    Berlin, 10117, Germany
  • Onkologische Schwerpunktpraxis Kurfürstendamm
    Berlin, 10707, Germany
  • Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin
    Bonn, 53127, Germany
  • Dres. Matthias Adler Oliver Marschal und Andreas Pies
    Braunschweig, 38100, Germany
  • Gemeinschaftspraxis
    Duisburg, 47051, Germany
  • Internistische Praxis Dr. Plingen
    Düsseldorf, 40211, Germany
  • Internistische Schwerpunktpraxis Erlangen
    Erlangen, 91052, Germany
  • Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
    Freiburg, 79110, Germany
  • Onkologische Gemeinschaftspraxis, Prof. Dr. Gropp, Dr. Depenbusch und Dr. Rösel
    Gütersloh, 33332, Germany
  • Überörtliche Gemeinschaftspraxis Schwerpunkt Hämatologie, internistische Onkologie & Palliativmed.
    Hamburg, 20259, Germany
  • Onkologische Schwerpunktpraxis; Herrn Dr. Med. Bertram
    Hamburg, 22457, Germany
  • Dres.Andreas Karcher und Stefan Fuxius
    Heidelberg, 69115, Germany
  • Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V
    Heidelberg, 69120, Germany
  • Onkologische Schwerpunktpraxis (Eps-Gmbh)
    Jena, 07743, Germany
  • Märkische Kliniken GmbH, Klinikum Lüdenscheid; Hämatologie / Onkologie
    Lüdenscheid, 58515, Germany
  • Stauferklinikum Schwäb.Gmünd
    Mutlangen, 73557, Germany
  • Gemeinschaftspraxis Dres. Schröder, Sieg
    Mülheim, 45468, Germany
  • Onko. Gemeinschaftspraxis Dres. Tigges/ Böning/ Abenhardt/ Bosse
    München, 80335, Germany
  • Dres.Ulrich Hutzschenreuter und Uwe Sauer
    Nordhorn, 48527, Germany
  • Onkologische Praxis Oldenburg; Dres. Otremba, Reschke, Zirpel, Kühn und Ruff
    Oldenburg, 26121, Germany
  • Praxis für Onkologie und Hämatologie
    Recklinghausen, 45657, Germany
  • Diakonie-Klinikum Klinik für Innere Medizin III Abt.Hämatologie, intern. Onkologie und Palliativmedi
    Schwäbisch-Hall, 74523, Germany
  • Internistische Gemeinschaftspraxis Dres. Hoering/Von Ehr/Responde
    Stuttgart, 70176, Germany
  • Haematologisch-Onkologische Praxis; Dr. med. Christoph Maintz und Matthias Groschek
    Wuerselen, 52146, Germany
  • Laiko General Hospital - Uni of Athens; 1St Dept. of Internal Medicine
    Athens, 11524, Greece
  • Attiko Hospital; Haematology Clinic
    Athens, 124 62, Greece
  • Theagenio Anticancer Hospital; Dept. of Haematology
    Thessaloniki, 54007, Greece
  • Rambam Medical Center; Heamatology & Bone Marrow Transplantation
    Haifa, 3109601, Israel
  • Wolfson Mc; Haematology
    Holon, 5810001, Israel
  • Hadassah Ein Karem Hospital; Haematology
    Jerusalem, 9112001, Israel
  • Chaim Sheba Medical Center; Hematology BMT & CBB
    Ramat Gan, 52662, Israel
  • Ichilov Sourasky Medical Center; Heamatology
    Tel Aviv, 6423906, Israel
  • Ospedale Civile Dello Spirito Santo; Divisione Di Ematologia
    Pescara, Abruzzo 65100, Italy
  • Az. Osp. Pugliese; Dh Oncologico
    Catanzaro, Calabria 88100, Italy
  • Ospedale S. Gennaro; Divisione Di Ematologia
    Napoli, Campania 80100, Italy
  • Ospedale Cardarelli; Divisione Di Ematologia
    Napoli, Campania 80131, Italy
  • A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna
    Bologna, Emilia-Romagna 40138, Italy
  • Arcispedale S. Anna; Sezione Di Ematologia
    Ferrara, Emilia-Romagna 44100, Italy
  • A.O. Universitaria Policlinico Di Modena; Ematologia
    Modena, Emilia-Romagna 41100, Italy
  • A.O.U. Policlinico di Modena-Dipartimento di Medicina Diagnostica, Clinica e di Sanità pubblica
    Modena, Emilia-Romagna 41100, Italy
  • Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
    Aviano, Friuli-Venezia Giulia 33081, Italy
  • Az. Osp. Uni Ria Policlinico Tor Vergata; Unita Di Ematologia
    Roma, Lazio 00133, Italy
  • Ospedale S. Eugenio; Divisione Di Ematologia
    Roma, Lazio 00144, Italy
  • Univ. Cattolica La Sapienza; Cattedra Di Ematologia
    Roma, Lazio 00161, Italy
  • Uni Cattolica; Divisione Di Ematologia
    Roma, Lazio 00168, Italy
  • A.O. Universitaria S. Martino Di Genova; Ematologia 1
    Genova, Liguria 16132, Italy
  • A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia
    Brescia, Lombardia 25123, Italy
  • Istituto S. Raffaele Monte Tabor; Divisione Ematologia E Utmo
    Milano, Lombardia 20132, Italy
  • Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico
    Milano, Lombardia 20133, Italy
  • Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
    Milano, Lombardia 20162, Italy
  • ASST DI MONZA; Ematologia
    Monza, Lombardia 20052, Italy

Showing the first 100 of 178 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Witzens-Harig M, Foa R, Di Rocco A, van Hazel G, Chamone DF, Rowe JM, Arcaini L, Poddubnaya I, Ho AD, Ivanova V, Vranovsky A, Thurley D, Oertel S. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol. 2014 Oct;93(10):1717-24. doi: 10.1007/s00277-014-2103-3. Epub 2014 May 14. Erratum In: Ann Hematol. 2014 Oct;93(10):1807. PubMed 24824768 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2006 to primary completion in May 2011, 56 months.

Results were first posted in Jun 2015, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2007
First posted
Feb 1, 2007
StartActual
Sep 4, 2006
Primary completionActual
May 26, 2011
CompletionActual
May 26, 2011
Results first posted
Jun 8, 2015
Last update
Aug 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00430352
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 1, 2007
Start date
Sep 4, 2006
Primary completion
May 26, 2011
Completion
May 26, 2011
Results posted
Jun 8, 2015
Last update
Aug 14, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion